PremiumThe FlyTrevi Therapeutics 17.4M share Secondary priced at $5.75 Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC PremiumRatingsBuy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities Trevi Therapeutics Reports Positive Phase 2b Trial Results Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio PremiumThe FlyTrevi Therapeutics provides additional analysis of Haduvio in chronic cough Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough Trevi Therapeutics’ Haduvio Phase 2b CORAL Study: A Potential Milestone in IPF Cough Treatment